Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas

Tumor Biology

Volumn 32, Issue 4, 2011, Pages 697-705

  Wang, De Shen ^a   Zhang, Dong Sheng ^a   Qiu, Miao Zhen ^a   Wang, Zhi Qiang ^a   Luo, Hui Yan ^a   Wang, Feng Hua ^a   Li, Yu Hong ^a   Xu, Rui Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Neuroendocrine tumors; Pancreas; Prognostic analysis; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; MITOMYCIN; STREPTOZOCIN;

ADOLESCENT; ADULT; AGED; ANOREXIA; ASCITES; BONE METASTASIS; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHINA; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GASTRINOMA; HORMONE SYNTHESIS; HUMAN; INSULINOMA; JAUNDICE; LIVER METASTASIS; LIVER RESECTION; MALE; NAUSEA; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; RADICAL RESECTION; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; VOMITING; WEIGHT REDUCTION;

EID: 80052311037     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0170-9     Document Type: Review

References (30)

1. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753-81. (Pubitemid 41614122)
2. Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008;15:409-27. (Pubitemid 351880831)
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-72.
4. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727-33.
5. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. Tnm staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401. (Pubitemid 44451313)
6. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci. 2004;1014:13-27. (Pubitemid 38594787)
7. Broughan TA, Leslie JD, Soto JM, Hermann RE. Pancreatic islet cell tumors. Surgery. 1986;99:671.
8. Phan GQ, Yeo CJ, Hruban RH, Littemoe KD, Pitt HA, Cameron JL. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg. 1998;2:473-82. (Pubitemid 128427984)
9. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247:490-500.
10. Wang SE, Su CH, Kuo YJ, Shyr YM, Li AF, Chen TH, et al. Comparison of functional and nonfunctional neuroendocrine tumors in the pancreas and peripancreatic region. Pancreas. 2011;40:253-9.
11. Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009;115:741-51.
12. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091-6.
13. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, et al. Prognostic factors at diagnosis and value of who classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol. 2008;19:903-8. (Pubitemid 351627305)
14. Schurr PG, Strate T, Rese K, Kaifi JT, Reichelt U, Petri S, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg. 2007;245:273-81. (Pubitemid 46148487)
15. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590-602. (Pubitemid 41437421)
16. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14:7798-803.
17. Ito H, Abramson M, Ito K, Swanson E, Cho N, Ruan DT, et al. Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience. J Gastrointest Surg. 2010;14:891-8.
18. Gao C, Fu X, Pan Y, Li Q. Surgical treatment of pancreatic neuroendocrine tumors: report of 112 cases. Dig Surg. 2010;27:197-204.
19. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980;303:1189-94. (Pubitemid 11207582)
20. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519-23.
21. Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase ii trial of dacarbazine (dtic) in advanced pancreatic islet cell carcinoma. Study of the eastern cooperative oncology groupe6282. Ann Oncol. 2001;12:1139-43. (Pubitemid 32834496)
22. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase ii study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24:401-6. (Pubitemid 46630459)
23. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81:1351-5.
24. Saltz L, Lauwers G, Wiseberg J, Kelsen D. A phase ii trial of carboplatin in patients with advanced apud tumors. Cancer. 1993;72:619-22. (Pubitemid 23193477)
25. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996;38:430-8.
26. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993;72:244-8. (Pubitemid 23182080)
27. Oberg K, Eriksson B, Janson ET. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors. Digestion. 1994;55 Suppl 3:64-9.
28. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients withmetastatic neuroendocrinemidgut tumors: a report from the promid study group. J Clin Oncol. 2009;27:4656-63.
29. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard- Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-13.
30. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-23.